<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35073950</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>11</StartPage><MedlinePgn>11</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00515-1</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staats</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Staats Life Sciences Consulting, LLC, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borchelt</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida College of Medicine, McKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tansey</LastName><ForeName>Mal&#xfa; G&#xe1;mez</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Center for Translational Research in Neurodegenerative Disease at The University of Florida College of Medicine, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0809-2977</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA. James.Wymer@neurology.ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35073950</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pii">10.1186/s13024-022-00515-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127&#x2013;1138. doi: 10.1016/S1474-4422(14)70129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016 [cited 2020]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK326791/</Citation><ArticleIdList><ArticleId IdType="pubmed">27010052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur R, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey L, Barohn RJ, Tandan R, Western ALS Study Group Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045&#x2013;1053. doi: 10.1016/S1474-4422(07)70270-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70270-3</ArticleId><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirzagar N, Nafissi S, Tafakhori A, Modabbernia A, Amirzargar A, Ghaffarpour M, Siroos B, Harirchian MH. Granulocyte Colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind. Placebo-Controlled Study of Iranian Patients J Clin Neurol. 2015;11(2):164. doi: 10.3988/jcn.2015.11.2.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2015.11.2.164</ArticleId><ArticleId IdType="pmc">PMC4387482</ArticleId><ArticleId IdType="pubmed">25851895</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Broadley S, Bedlack R, Russo E, Sabet A. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease pRogression of amyotrophic lateral sclerosis or motor neurone disease: the EMERALD trial. BMJ Open. 2019;9(11):e029449. doi: 10.1136/bmjopen-2019-029449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-029449</ArticleId><ArticleId IdType="pmc">PMC6858175</ArticleId><ArticleId IdType="pubmed">31719072</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, Mar&#xed;n S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O, on behalf of the AB10015 STUDY GROUP Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener. 2020;21(1-2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten J, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, H&#xf6;ltt&#xe4;-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chi&#xf2; A, Restagno G, Borghero G, Sabatelli M, ITALSGEN Consortium. Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NCA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GYR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chi&#xf2; A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7(1):12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Barp A, Gerardi F, Lizio A, Sansone VA, Lunetta C. Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials. Expert Opin Emerg Drugs. 2020;25(2):145&#x2013;164. doi: 10.1080/14728214.2020.1769067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728214.2020.1769067</ArticleId><ArticleId IdType="pubmed">32456491</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8(1):94&#x2013;109. doi: 10.1016/S1474-4422(08)70293-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70293-X</ArticleId><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, Schultz D, Benatar M, Rogers ML. Urinary p75ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265(3):510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, Mayer B, M&#xfc;ller HP, Gorges M, Rosenbohm A, Volk AE, Silani V, Ludolph AC, Otto M. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279. doi: 10.3389/fneur.2020.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10(3):253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph Lateral Scler Front Degener. 2014;15(5-6):453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019;7(1):3. doi: 10.1186/s40364-019-0154-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40364-019-0154-2</ArticleId><ArticleId IdType="pmc">PMC6373155</ArticleId><ArticleId IdType="pubmed">30805188</ArticleId></ArticleIdList></Reference><Reference><Citation>Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy&#x2014;diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157&#x2013;169. doi: 10.1002/mus.27046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27046</ArticleId><ArticleId IdType="pubmed">32914902</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter L, Shoushtarizadeh A, Jelinek GA, Brown CR, Lim CK, de Livera AM, Jacobs KR, Weiland TJ. Metabolomic biomarkers of multiple sclerosis: a systematic review. Front Mol Biosci. 2020;7:574133. doi: 10.3389/fmolb.2020.574133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.574133</ArticleId><ArticleId IdType="pmc">PMC7768024</ArticleId><ArticleId IdType="pubmed">33381517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor AM, Shy ME, Reilly MM. Are we prepared for clinical trials in Charcot-Marie-tooth disease? Brain Res. 1729;2020:146625. doi: 10.1016/j.brainres.2019.146625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146625</ArticleId><ArticleId IdType="pmc">PMC8418667</ArticleId><ArticleId IdType="pubmed">31899213</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, Thonhoff JR, Thome AD, Faridar A, Wen S, Wang J, Appel SH. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):15295. doi: 10.1038/s41598-020-72247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941. doi: 10.1038/s41598-020-62756-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, Artamonov I, Drory VE. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;119(6):383&#x2013;389. doi: 10.1111/j.1600-0404.2008.01112.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2008.01112.x</ArticleId><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Zecca C, Piccininni M, Benmahamed S, Dell&#x2019;Abate MT, Barulli MR, et al. Plasma inflammatory cytokines are elevated in ALS. Front Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty L, Henderson RD, McCombe PA, Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotroph Lateral Scler Front Degener. 2020;21(7-8):1&#x2013;4. doi: 10.1080/21678421.2020.1779303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779303</ArticleId><ArticleId IdType="pubmed">32558599</ArticleId></ArticleIdList></Reference><Reference><Citation>Polverino A, Rucco R, Stillitano I, Bonavita S, Grimaldi M, Minino R, Pesoli M, Trojsi F, D'Ursi AM, Sorrentino G, Sorrentino P. In amyotrophic lateral sclerosis blood cytokines are altered, but do not correlate with changes in brain topology. Brain Connect. 2020;10(8):411&#x2013;421. doi: 10.1089/brain.2020.0741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/brain.2020.0741</ArticleId><ArticleId IdType="pubmed">32731760</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH, Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103&#x2013;1116. doi: 10.1002/acn3.51078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J Neurol Sci. 2019;398:50&#x2013;53. doi: 10.1016/j.jns.2019.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>de Prado L. GR, Rocha NP, de Souza LC, Bicalho ICS, Gomez RS, Vidigal-Lopes M, et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis J Neurol Sci. 2018;394:69&#x2013;74. doi: 10.1016/j.jns.2018.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId><ArticleId IdType="pubmed">30219498</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Dom&#xed;nguez R, Aso E, Povedano M, Ferrer I. Inflammatory gene expression in whole peripheral blood at early stages of sporadic amyotrophic lateral sclerosis. Front Neurol. 2017;8:546. doi: 10.3389/fneur.2017.00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00546</ArticleId><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-Plotkin A, Wolk DA, McCluskey LF, Elman LB, Trojanowski JQ, Umansky SR. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther. 2017;9(1):89. doi: 10.1186/s13195-017-0316-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0316-0</ArticleId><ArticleId IdType="pmc">PMC5679501</ArticleId><ArticleId IdType="pubmed">29121998</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho AC. Gromicho M, Pereira M, Pinto S, Barros M do a, Swash M, et al. plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis. Acta Neurol Scand. 2018;137(2):233&#x2013;237. doi: 10.1111/ane.12851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12851</ArticleId><ArticleId IdType="pubmed">28967121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin X-Y, Yu Y, Yuan J, Zhao Y, Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, Vourc&#x2019;h P, Andres CR, Corcia P. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci J Can Sci Neurol. 2017;44(1):90&#x2013;95. doi: 10.1017/cjn.2016.284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.284</ArticleId><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Boss&#xf9; P, Migliorini P, Siciliano G, Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11(1):94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CY, Pfluger CM, Henderson RD, McCombe PA. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J Neuroimmunol. 2012;249(1-2):93&#x2013;95. doi: 10.1016/j.jneuroim.2012.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.05.001</ArticleId><ArticleId IdType="pubmed">22633272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation. 2010;7(1):76. doi: 10.1186/1742-2094-7-76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, Grant R, Brew BJ, Guillemin GJ. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18(2):132&#x2013;142. doi: 10.1007/s12640-009-9129-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9129-7</ArticleId><ArticleId IdType="pubmed">19921535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RLP, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16(6):771&#x2013;774. doi: 10.1111/j.1468-1331.2009.02560.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu GN, Kumar A, Chandra R, Puri SK, Kalita J, Misra UK. Elevated inflammatory markers in a Group of Amyotrophic Lateral Sclerosis Patients from northern India. Neurochem Res. 2008;33(6):1145&#x2013;1149. doi: 10.1007/s11064-007-9564-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9564-x</ArticleId><ArticleId IdType="pubmed">18246426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, Tsoutsou A, Vassilopoulos D. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(5):283&#x2013;287. doi: 10.1080/17482960701419232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701419232</ArticleId><ArticleId IdType="pubmed">17852013</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton SB, Shaw PJ, Silani V. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32(4):541&#x2013;544. doi: 10.1002/mus.20376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20376</ArticleId><ArticleId IdType="pubmed">15962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilms H. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol. 2003;144(1-2):139&#x2013;142. doi: 10.1016/j.jneuroim.2003.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2003.08.042</ArticleId><ArticleId IdType="pubmed">14597108</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber M, Romero P, Wurdinger T, Xavier R, Geissmann F, Meylan E, Nahrendorf M, Swirski FK, Baltimore D, Weissleder R, Pittet MJ. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 2012;1(4):317&#x2013;324. doi: 10.1016/j.celrep.2012.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.02.009</ArticleId><ArticleId IdType="pmc">PMC3334310</ArticleId><ArticleId IdType="pubmed">22545247</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack SA, Dunlop RA, Cox PA. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol. 2020;10(6):200116. doi: 10.1098/rsob.200116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.200116</ArticleId><ArticleId IdType="pmc">PMC7333885</ArticleId><ArticleId IdType="pubmed">32574550</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Front Degener. 2018;19(5-6):362&#x2013;376. doi: 10.1080/21678421.2018.1433689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1433689</ArticleId><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O&#x2019;Rourke JG, Y&#xe1;&#xf1;ez A, Markman JL, Ho R, Wang X, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner C, Perner F, Stubendorff B, F&#xf6;rster M, Witte OW, Heidel FH, Prell T, Grosskreutz J. Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. J Neuroinflammation. 2018;15(1):99. doi: 10.1186/s12974-018-1135-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1135-3</ArticleId><ArticleId IdType="pmc">PMC5874995</ArticleId><ArticleId IdType="pubmed">29592817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusconi M, Gerardi F, Santus W, Lizio A, Sansone VA, Lunetta C, Zanoni I, Granucci F. Inflammatory role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients&#x2019; peripheral blood. Sci Rep. 2017;7(1):7853. doi: 10.1038/s41598-017-08233-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08233-1</ArticleId><ArticleId IdType="pmc">PMC5552769</ArticleId><ArticleId IdType="pubmed">28798369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP. Bornschlegl S, Butler GW, Maas ML, Kazamel M, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. Raoul C, editor. PLOS ONE. 2017;12:e0182002. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, Traini CM, Halsey WS, Hughes AM, Sathe GM, Livi GP, Fan GH, Appel SH. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 2017;74(6):677&#x2013;685. doi: 10.1001/jamaneurol.2017.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam L, Chin L, Halder RC, Sagong B, Famenini S, Sayre J, Montoya D, Rubbi L, Pellegrini M, Fiala M. Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. FASEB J Off Publ Fed Am Soc Exp Biol. 2016;30(10):3461&#x2013;3473. doi: 10.1096/fj.201600259RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201600259RR</ArticleId><ArticleId IdType="pmc">PMC5024692</ArticleId><ArticleId IdType="pubmed">27368295</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, Lunetta C, Corbo M, Rovaris M, Clerici M. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148(1):79&#x2013;88. doi: 10.1016/j.clim.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Mizwicki MT, Weitzman R, Magpantay L, Nishimoto N. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis. 2013;2(2):129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703125</ArticleId><ArticleId IdType="pubmed">23844337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, Martinez-Maza O, Chattopadhyay M, la Cava A. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2005;159(1-2):215&#x2013;224. doi: 10.1016/j.jneuroim.2004.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.10.009</ArticleId><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Gustavsen S, Gissel&#xf8; Lauridsen K, Chenoufi Hasselbalch I, Sellebjerg F, Bach S&#xf8;ndergaard H, Bang Oturai A. Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: a systematic review. Acta Neurol Scand. 2021;143(6):577&#x2013;586. doi: 10.1111/ane.13401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13401</ArticleId><ArticleId IdType="pubmed">33591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gururaj S, Sampognaro PJ, Argouarch AR, Kao AW. Progranulin adsorbs to polypropylene tubes and disrupts functional assays: implications for research, biomarker studies, and therapeutics. Front Neurosci. 2020;14:602235. doi: 10.3389/fnins.2020.602235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.602235</ArticleId><ArticleId IdType="pmc">PMC7768044</ArticleId><ArticleId IdType="pubmed">33381010</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, Bruijn L. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve. 2016;53(2):169&#x2013;182. doi: 10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur N, Huss E, Prell T, Steinbach R, Guerra J, Srivastava A, Witte OW, Grosskreutz J. Monocyte-derived macrophages contribute to Chitinase dysregulation in amyotrophic lateral sclerosis: a pilot study. Front Neurol. 2021;12:629332. doi: 10.3389/fneur.2021.629332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.629332</ArticleId><ArticleId IdType="pmc">PMC8160083</ArticleId><ArticleId IdType="pubmed">34054686</ArticleId></ArticleIdList></Reference><Reference><Citation>. F. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.</Citation></Reference><Reference><Citation>Sun J, Carrero JJ, Zagai U, Evans M, Ingre C, Pawitan Y, Fang F. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(11):2125&#x2013;2133. doi: 10.1111/ene.14409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2020:1&#x2013;11.</Citation></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, Appel SH, Chi&#xf2; A. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(6):660&#x2013;667. doi: 10.1001/jamaneurol.2016.6179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Moreau C, Kyheng M, Gar&#xe7;on G, Rolland AS, Blasco H, Gel&#xe9; P, Timoth&#xe9;e Lenglet T, Veyrat-Durebex C, Corcia P, Dutheil M, Bede P, Jeromin A, Oeckl P, Otto M, Meininger V, Danel-Brunaud V, Devedjian JC, Duce JA, Pradat PF. A ferroptosis&#x2013;based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):2918. doi: 10.1038/s41598-019-39739-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39739-5</ArticleId><ArticleId IdType="pmc">PMC6393674</ArticleId><ArticleId IdType="pubmed">30814647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, la Cava A, Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560453</ArticleId><ArticleId IdType="pubmed">22787561</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Front Degener. 2014;15(7-8):601&#x2013;609. doi: 10.3109/21678421.2014.951940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951940</ArticleId><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain J Neurol. 1995;118(Pt 3):707&#x2013;719. doi: 10.1093/brain/118.3.707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.707</ArticleId><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng H-J, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, van den Berg LH. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451&#x2013;e460. doi: 10.1212/WNL.0000000000006855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, K&#xf6;rner S, Ringer TM, R&#xf6;diger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, van Damme P, Talbot K, Turner MR, Shaw PJ, al-Chalabi A, Chi&#xf2; A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20(5-6):303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainberg M, Magis AT, Earls JC, Lovejoy JC, Sinnott-Armstrong N, Omenn GS, Hood L, Price ND. Multiomic blood correlates of genetic risk identify presymptomatic disease alterations. Proc Natl Acad Sci. 2020;117(35):21813&#x2013;21820. doi: 10.1073/pnas.2001429117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2001429117</ArticleId><ArticleId IdType="pmc">PMC7474629</ArticleId><ArticleId IdType="pubmed">32817414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Shen X, Li J, Suckling J, Tan C, Wang Y, et al. Clinical and biomarker trajectories in sporadic Alzheimer&#x2019;s disease: A longitudinal study. Alzheimers Dement Diagn Assess Dis Monit. 2020;12 Available from: https://onlinelibrary.wiley.com/doi/10.1002/dad2.12095. Cited 2021 Feb 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12095</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H, for the Airlie House ALS Clinical Trials Guidelines Group Revised Airlie house consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumert B, Sobu&#x15b; A, Go&#x142;&#x105;b-Janowska M, Paczkowska E, &#x141;uczkowska K, Rogi&#x144;ska D, Zawi&#x15b;lak A, Milczarek S, Os&#x119;kowska B, Pawlukowska W, Meller A, Machowska-Sempruch K, We&#x142;nicka A, Safranow K, Nowacki P, Machali&#x144;ski B. Repeated application of autologous bone marrow-derived lineage-negative stem/progenitor cells&#x2014;focus on immunological pathways in patients with ALS. Cells. 2020;9(8):1822. doi: 10.3390/cells9081822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9081822</ArticleId><ArticleId IdType="pmc">PMC7463801</ArticleId><ArticleId IdType="pubmed">32752182</ArticleId></ArticleIdList></Reference><Reference><Citation>Milligan C, Atassi N, Babu S, Barohn RJ, Caress JB, Cudkowicz ME, Evora A, Hawkins GA, Wosiski-Kuhn M, Macklin EA, Shefner JM, Simmons Z, Bowser RP, Ladha SS. Tocilizumab is safe and tolerable and reduces C -reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021;64(3):309&#x2013;320. doi: 10.1002/mus.27339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27339</ArticleId><ArticleId IdType="pubmed">34075589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J. Rethinking amyotrophic lateral sclerosis. Mayo Clin Proc. 2018;93(11):1543&#x2013;1545. doi: 10.1016/j.mayocp.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.09.009</ArticleId><ArticleId IdType="pubmed">30392539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912&#x2013;920. doi: 10.1111/j.1398-9995.2006.01058.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1398-9995.2006.01058.x</ArticleId><ArticleId IdType="pubmed">16867042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499&#x2013;521. doi: 10.1586/eci.09.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eci.09.31</ArticleId><ArticleId IdType="pubmed">20477639</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Phase 1&#x2013;2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Delhaas EM, Huygen FJPM. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020;20(2):51&#x2013;57. doi: 10.1016/j.bjae.2019.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjae.2019.11.002</ArticleId><ArticleId IdType="pmc">PMC7807963</ArticleId><ArticleId IdType="pubmed">33456930</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of Oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23(30):7697&#x2013;7702. doi: 10.1200/JCO.2005.02.4364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.02.4364</ArticleId><ArticleId IdType="pubmed">16186597</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of Neuroinflammatory Responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119. doi: 10.3390/brainsci10020119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10020119</ArticleId><ArticleId IdType="pmc">PMC7071492</ArticleId><ArticleId IdType="pubmed">32098339</ArticleId></ArticleIdList></Reference><Reference><Citation>Je G, Keyhanian K, Ghasemi M. Overview of stem cells therapy in amyotrophic lateral sclerosis. Neurol Res. 2021;43(8):1&#x2013;17. doi: 10.1080/01616412.2021.1893564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.2021.1893564</ArticleId><ArticleId IdType="pubmed">33632084</ArticleId></ArticleIdList></Reference><Reference><Citation>Research C for BE and. Update on Amyotrophic Lateral Sclerosis (ALS) Product Development. FDA. FDA; 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/update-amyotrophic-lateral-sclerosis-als-product-development. Cited 2021 Apr 7.</Citation></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath M, Ludington E, Appel SH, Azhir A, Phase 2 Trial NP001 Investigators Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflammation. 2015;2(3):e100. doi: 10.1212/NXI.0000000000000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, Wolbert J, Heming M, Meuth SG, Kuhlmann T, Gross CC, Wiendl H, Yosef N, Meyer zu Horste G. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11(1):247. doi: 10.1038/s41467-019-14118-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14118-w</ArticleId><ArticleId IdType="pmc">PMC6959356</ArticleId><ArticleId IdType="pubmed">31937773</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, et al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018;58(2):261&#x2013;269. doi: 10.1002/mus.26106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26106</ArticleId><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori M, Nuzziello N, Introna A, Consiglio A, Licciulli F, D&#x2019;Errico E, Scarafino A, Distaso E, Simone IL. Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front Mol Neurosci. 2018;11:288. doi: 10.3389/fnmol.2018.00288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00288</ArticleId><ArticleId IdType="pmc">PMC6121079</ArticleId><ArticleId IdType="pubmed">30210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS) Neurobiol Aging. 2017;55:123&#x2013;131. doi: 10.1016/j.neurobiolaging.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JHM, Schorge S, Lamottke K, Rosenow F. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016;15(13):1368&#x2013;1376. doi: 10.1016/S1474-4422(16)30246-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30246-0</ArticleId><ArticleId IdType="pubmed">27839653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinar A, Koritnik B, Glava&#x10d; D, Ravnik-Glava&#x10d; M. Circular RNAs as potential blood biomarkers in amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56(12):8052&#x2013;8062. doi: 10.1007/s12035-019-1627-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1627-x</ArticleId><ArticleId IdType="pmc">PMC6834740</ArticleId><ArticleId IdType="pubmed">31175544</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Diaz N, Adelsberger J, Zhou X, Stevens R, Rupert A, Metcalf JA, Baseler M, Barbon C, Imamichi T, Lempicki R, Cosentino LM. The effects of storage temperature on PBMC gene expression. BMC Immunol. 2016;17(1):6. doi: 10.1186/s12865-016-0144-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-016-0144-1</ArticleId><ArticleId IdType="pmc">PMC4791795</ArticleId><ArticleId IdType="pubmed">26979060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degenerations&#x2014;Progress and challenges. Prog Neurobiol. 2011;95(4):636&#x2013;648. doi: 10.1016/j.pneurobio.2011.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.04.012</ArticleId><ArticleId IdType="pmc">PMC3173583</ArticleId><ArticleId IdType="pubmed">21554923</ArticleId></ArticleIdList></Reference><Reference><Citation>Poste G. Bring on the biomarkers. Nature. 2011;469(7329):156&#x2013;157. doi: 10.1038/469156a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/469156a</ArticleId><ArticleId IdType="pubmed">21228852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>